Suven Life Sciences Q3 net loss widens to Rs 34 cr

Capital Market 

Suven Life Sciences' consolidated net loss stood at Rs 33.69 crore in Q3 FY22 as compared to a net loss of Rs 24.39 crore in Q3 FY21.

Consolidated net sales soared 193.4% to Rs 4.43 crore in Q3 December 2021 over Rs 1.51 crore in Q3 December 2020. R&D and Operational expenses surged 31.11% to Rs 36.91 crore in Q3 FY22 as against Rs 28.15 crore in Q3 FY21.

Consolidated financial cost skid 7.14% to Rs 0.13 crore in Q3 FY22 as against Rs 0.14 crore in Q3 FY21. Total expenses grew 30% to Rs 38.26 crore in Q3 December 2021 as compared to Rs 29.43 crore in Q3 December 2020.

Shares of Suven Life Sciences lost 0.34% to end at Rs 89 on BSE. Suven Life Science is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, January 31 2022. 17:40 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU